Not Just Exxon: Paul Weiss Defends Many Rogue Corporations
From Big Tobacco to opioid crisis profiteering, Paul, Weiss, Rifkind, Wharton & Garrison LLP has made millions from defending some of the most repugnant corporate villains of recent decades
Page 6
From Big Tobacco to opioid crisis profiteering, Paul, Weiss, Rifkind, Wharton & Garrison LLP has made millions from defending some of the most repugnant corporate villains of recent decades
In touting the endorsement of Josh Black, the Buttigieg campaign declined to mention that Black now works for the pharmaceutical industry’s top lobbying group.
More than a dozen high-powered lawyers and executives, including the man who inspired Gordon Gekko, will help “Middle-Class Joe” raise campaign cash in early January.
Kristen Hawn, a communications consultant, appears on emails with industry-backed groups strategizing against health care changes.
The staffers, several of whom work for reps on the subcommittee overseeing pharmaceuticals, met with executives from drug companies Merck and Genentech.
After Rep. Greg Walden, the biggest recipient of pharmaceutical campaign cash in the last election cycle, met with Trump, the president decided to scrap his support for lower drug prices.
The industry-led Partnership for America’s Health Care Future, which has assailed Democratic presidential candidates’ reform plans, is drawing on Democratic firms for assistance.
The leading pharmaceutical lobby gave to numerous Republican groups—and one key Democratic one.
Freshman Rep. Anthony Brindisi (D-N.Y.) is advocating a 10-year exclusivity period for biologic drugs as the Blue Dog PAC takes maxed-out donations from the pharmaceutical industry.
With a clearer picture of how Medicare for All can be financed through reducing military spending, voters can debate the merits of a single-payer system without needing to consider any new taxes.